IL289884B2 - Oral formulations of cardiac sarcomere inhibitors - Google Patents

Oral formulations of cardiac sarcomere inhibitors

Info

Publication number
IL289884B2
IL289884B2 IL289884A IL28988422A IL289884B2 IL 289884 B2 IL289884 B2 IL 289884B2 IL 289884 A IL289884 A IL 289884A IL 28988422 A IL28988422 A IL 28988422A IL 289884 B2 IL289884 B2 IL 289884B2
Authority
IL
Israel
Prior art keywords
granular
weight
total core
intra
core weight
Prior art date
Application number
IL289884A
Other languages
English (en)
Hebrew (he)
Other versions
IL289884B1 (en
IL289884A (en
Inventor
Qiao Chunsheng
Original Assignee
Cytokinetics Inc
Qiao Chunsheng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, Qiao Chunsheng filed Critical Cytokinetics Inc
Publication of IL289884A publication Critical patent/IL289884A/en
Publication of IL289884B1 publication Critical patent/IL289884B1/en
Publication of IL289884B2 publication Critical patent/IL289884B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL289884A 2019-07-17 2020-07-16 Oral formulations of cardiac sarcomere inhibitors IL289884B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875358P 2019-07-17 2019-07-17
PCT/US2020/042389 WO2021011808A1 (en) 2019-07-17 2020-07-16 Cardiac sarcomere inhibitor oral formulations

Publications (3)

Publication Number Publication Date
IL289884A IL289884A (en) 2022-03-01
IL289884B1 IL289884B1 (en) 2025-09-01
IL289884B2 true IL289884B2 (en) 2026-01-01

Family

ID=71995104

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289884A IL289884B2 (en) 2019-07-17 2020-07-16 Oral formulations of cardiac sarcomere inhibitors

Country Status (25)

Country Link
US (1) US20220265612A1 (https=)
EP (1) EP3999038B1 (https=)
JP (1) JP7623342B2 (https=)
KR (1) KR20220082804A (https=)
CN (1) CN114765954B (https=)
AU (1) AU2020315642B2 (https=)
BR (1) BR112022000495A2 (https=)
CA (1) CA3144972A1 (https=)
CL (1) CL2022000108A1 (https=)
DK (1) DK3999038T3 (https=)
ES (1) ES2974542T3 (https=)
FI (1) FI3999038T3 (https=)
HR (1) HRP20240200T1 (https=)
HU (1) HUE065712T2 (https=)
IL (1) IL289884B2 (https=)
LT (1) LT3999038T (https=)
MX (1) MX2022000708A (https=)
PH (1) PH12022550083A1 (https=)
PL (1) PL3999038T3 (https=)
PT (1) PT3999038T (https=)
RS (1) RS65302B1 (https=)
SI (1) SI3999038T1 (https=)
SM (1) SMT202400107T1 (https=)
TW (1) TW202519217A (https=)
WO (1) WO2021011808A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
PT4370116T (pt) 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
WO2024020468A1 (en) 2022-07-20 2024-01-25 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
EP4565230A1 (en) 2022-08-04 2025-06-11 Cytokinetics, Inc. Methods for treating obstructive hypertrophic cardiomyopathy
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
US20250295639A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
NZ598744A (en) * 2009-09-18 2013-11-29 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
US20130273096A1 (en) * 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
WO2013112804A1 (en) * 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US9199945B2 (en) * 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US20170087180A1 (en) * 2014-06-03 2017-03-30 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
ES2969565T3 (es) * 2015-09-30 2024-12-13 Max Planck Ges Zur Foerderung Derwissenschaften E V Derivados heteroarílicos como inhibidores de la sepiapterina reductasa
WO2019144041A1 (en) * 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Also Published As

Publication number Publication date
PH12022550083A1 (en) 2023-04-12
PL3999038T3 (pl) 2024-05-13
TW202116307A (zh) 2021-05-01
RS65302B1 (sr) 2024-04-30
IL289884B1 (en) 2025-09-01
IL289884A (en) 2022-03-01
MX2022000708A (es) 2022-02-23
BR112022000495A2 (pt) 2022-03-03
NZ784934A (en) 2025-03-28
US20220265612A1 (en) 2022-08-25
AU2020315642B2 (en) 2026-04-02
CL2022000108A1 (es) 2022-10-21
DK3999038T3 (da) 2024-03-18
KR20220082804A (ko) 2022-06-17
HRP20240200T1 (hr) 2024-04-26
FI3999038T3 (fi) 2024-02-21
EP3999038A1 (en) 2022-05-25
ES2974542T3 (es) 2024-06-27
TW202519217A (zh) 2025-05-16
PT3999038T (pt) 2024-03-14
AU2020315642A1 (en) 2022-03-03
CN114765954B (zh) 2024-01-02
JP7623342B2 (ja) 2025-01-28
JP2022542804A (ja) 2022-10-07
EP3999038B1 (en) 2024-01-10
LT3999038T (lt) 2024-03-25
SMT202400107T1 (it) 2024-05-14
WO2021011808A1 (en) 2021-01-21
HUE065712T2 (hu) 2024-06-28
CA3144972A1 (en) 2021-01-21
SI3999038T1 (sl) 2024-05-31
CN114765954A (zh) 2022-07-19

Similar Documents

Publication Publication Date Title
IL289884B1 (en) Oral formulations of cardiac sarcomere inhibitors
EP3999180B1 (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
IL259493A (en) Solid dispersions containing sgc actuator
IL305628A (en) Cardiac sarcomere inhibitors
US20220274969A1 (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
WO2024050539A1 (en) Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde
TW202423424A (zh) 治療阻塞型肥厚性心肌病之方法
RU2823999C2 (ru) Пероральные композиции ингибиторов сердечного саркомера
TWI917329B (zh) 心臟肌小節抑制劑口服調配物
IL287727B2 (en) Use of phenoxypropylamine compounds to treat depression
HK40077275A (en) Cardiac sarcomere inhibitor oral formulations
JP2024508686A (ja) フォスプロポフォールの方法及び組成物
HK40077275B (zh) 心脏肌节抑制剂口服制剂
HK40076616A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40075684A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
IL323241A (en) Solid-state pyrrolidone derivative as a glucokinase activator